Streetbeat News

Stock Prices

BIMI

BIMI International Medical Inc. received a notification from Nasdaq for non-compliance with Listing Rule 5250(c)(1) due to not filing its Q3 Form 10-Q. The company had previously been granted an extension to file its Q2 Form 10-Q, which it has now filed. BIMI must submit an updated plan to regain compliance, with a deadline of February 20, 2024, to file all delinquent reports.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 1:25 pm

CHEK

Check-Cap (NASDAQ:CHEK) reported Q3 earnings with an EPS of $-0.44, missing estimates by 51.72% compared to the expected $-0.29. Revenue was unchanged from the same period last year. Despite missing EPS last quarter, CHEK's share price increased by 3.86% the following day.

Portfolio Pulse from Benzinga Insights

November 27, 2023 | 1:25 pm

SCCO

Southern Copper (SCCO) shares have declined following a downgrade by Morgan Stanley analysts, who changed the stock's rating to Underweight.

Portfolio Pulse from Luke J Jacobi

November 27, 2023 | 1:24 pm

WHLR

Wheeler Real Estate Investment Trust, Inc. (NASDAQ:WHLR) anticipates issuing unregistered common stock to fulfill Series D Preferred Stock redemption requests due to insufficient registered shares. The decline in WHLR's stock price and high volume of redemptions are cited as reasons. The company intends to register the unregistered shares later.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 1:23 pm

SHOP

Shopify (SHOP) stock is trading higher following the announcement of robust Black Friday sales.

Portfolio Pulse from Luke J Jacobi

November 27, 2023 | 1:22 pm

LCID

Lucid Group, Inc. (NASDAQ:LCID) shares dropped in premarket trading after Needham analyst Chris Pierce downgraded the stock from Buy to Hold. The downgrade was due to reduced unit estimates following Lucid's disappointing quarterly results and less optimism about Lucid's ability to license its EV technology to Aston Martin. Despite the downgrade, Pierce was positive about Lucid's new Gravity SUV. Lucid's stock fell 1.21% to $4.188 in premarket trading.

Portfolio Pulse from Shanthi Rexaline

November 27, 2023 | 1:21 pm

VINE

Fresh Vine Wine, Inc. (NYSE:VINE) received an Acceptance Letter from NYSE American confirming the acceptance of its compliance plan. The company was previously notified of non-compliance with the stockholders' equity requirement of Section 1003(a)(ii) of the NYSE American Company Guide, having reported stockholders' equity below $4 million and losses in recent fiscal years. Fresh Vine Wine reported $2.4 million in equity as of June 30, 2023, and $1.1 million as of September 30, 2023. The company has until March 8, 2025, to regain compliance with Sections 1003(a)(i) and (ii), during which it will be subject to periodic reviews and risk of delisting if it fails to comply. Its stock will continue to trade under the symbol 'VINE' with a '.BC' indicator signaling noncompliance.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 1:19 pm

BRD

Beard Energy Transition Acquisition Corp. (BRD) and Suntuity Renewables have mutually agreed to terminate their business combination agreement. Consequently, BRD will not proceed with the special meeting to extend the deadline for a business combination and intends to dissolve and liquidate. BRD will redeem all outstanding Class A common stock at approximately $10.74 per share, with the last trading day on December 11, 2023. BRD's warrants will expire worthless, and the company will cease operations after December 12, 2023, except for winding up its business. BRD will also delist from the NYSE and terminate the registration of its securities.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 1:14 pm

SYTA

Siyata Mobile Inc. has received a purchase order for its SD7 rugged handsets and VK7 vehicle kits, which will be used in a new vertical market. This development could indicate an expansion of Siyata's market reach and potential growth in sales.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 1:14 pm

CATX

Perspective Therapeutics has announced the publication of four preclinical studies that support the company's discovery pipeline. These studies are crucial for the advancement of the company's research and development efforts in creating innovative treatments. The announcement is likely to be viewed positively by investors as it demonstrates progress in the company's pipeline.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 1:13 pm